Atossa Therapeutics Inc. (NASDAQ: ATOS) received feedback from the U.S. Food and Drug Administration regarding its proposed dose optimization trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE